Hostname: page-component-6766d58669-7fx5l Total loading time: 0 Render date: 2026-05-19T00:39:11.834Z Has data issue: false hasContentIssue false

Seroprevalence of parvovirus B19 in the German population

Published online by Cambridge University Press:  16 January 2008

C. RÖHRER
Affiliation:
Institut für Medizinische Mikrobiologie und Hygiene, Universität Regensburg, Regensburg, Germany
B. GÄRTNER
Affiliation:
Institut für Virologie, Universitätsklinikum des Saarlands, Homburg/Saar, Germany
A. SAUERBREI
Affiliation:
Institut für Virologie und Antivirale Therapie, Jena, Germany
S. BÖHM
Affiliation:
Institut für Medizinische Mikrobiologie und Hygiene, Universität Regensburg, Regensburg, Germany
B. HOTTENTRÄGER
Affiliation:
Institut für Medizinische Mikrobiologie und Hygiene, Universität Regensburg, Regensburg, Germany
U. RAAB
Affiliation:
Institut für Medizinische Mikrobiologie und Hygiene, Universität Regensburg, Regensburg, Germany
W. THIERFELDER
Affiliation:
Robert-Koch-Institut, Berlin, Germany
P. WUTZLER
Affiliation:
Institut für Virologie und Antivirale Therapie, Jena, Germany
S. MODROW*
Affiliation:
Institut für Medizinische Mikrobiologie und Hygiene, Universität Regensburg, Regensburg, Germany
*
*Author for correspondence: Prof. Dr S. Modrow, Institut für Medizinische Mikrobiologie und Hygiene, Universität Regensburg, Franz-Josef-Strauß-Allee 11, 93053 Regensburg, Germany. (Email: susanne.modrow@klinik.uni-regensburg.de)
Rights & Permissions [Opens in a new window]

Summary

Acute parvovirus B19 infection is a risk for pregnant women. After vertical transmission the infected fetus may develop hydrops fetalis. Since B19 infection occurs mainly during childhood, children represent a main source for virus transmission. In order to determine whether certain groups in the German population show increased risks for B19 infection we analysed the seroprevalence using 6583 sera collected from adults in former Eastern and Western Germany during the German National Health Survey and 649 sera from healthy Thuringian children and adolescents. In adults the overall seroprevalence was 72·1%, rising from 20·4% in children (1–3 years) and 66·9% in adolescents (18–19 years) to 79·1% in the elderly (65–69 years). Significant differences were observed between females (73·3%) and males (70·9%) and between inhabitants of small (74·8%) and big cities (69·0%) but not between people of the former Eastern (72·8%) and Western states (72·0%) of Germany. For women during childbearing age (18–49 years) highest values were observed in those living together with two or more children (81·6%) and in women with occupational contact with children aged <6 years (88·9%). In contrast seroprevalence was significantly lower in age-matched female singles (64·8%) and in women with occupational contact with children aged >6 years and adolescents (63·8%).

Information

Type
Original Papers
Copyright
Copyright © 2008 Cambridge University Press
Figure 0

Fig. 1. Seroprevalence of parvovirus B19 in the adult population (males and females) in Germany according to age (years). ■, Seropositive individuals; , equivocal;□, seronegative.

Figure 1

Table 1. Seroprevalence of IgG against VP1/VP2 proteins of parvovirus B19 in the adult population (18–79 years) given in 5-year intervals

Figure 2

Table 2. Seroprevalence of parvovirus B19 of the adult population (18–79 years) according to the living situation in rural regions (<5000 inhabitants), small (5000–19 999 inhabitants), medium-sized (20 000–100 000 inhabitants) and big cities (>100 000 inhabitants)

Figure 3

Fig. 2. Average titres (IU/ml) observed in seropositive infants aged <1 year (0–12 months). 0 months=blood samples obtained at time of birth.

Figure 4

Table 3(a). Prevalence of IgG against VP1/VP2 proteins of parvovirus B19 in newborns and young children aged <1 year (0–12 months)

Figure 5

Fig. 3. Seroprevalence of parvovirus B19 in children (1–18 years). Children were divided into subgroups according to the German system for education: day nursery (12–36 months/1–3 years); kindergarten (37–72 months/3–6 years); elementary school (73–120 months/6–10 years); secondary school (121–180 months/10–15 years); grammar school (181–216 months/15–18 years).

Figure 6

Table 3(b). Prevalence of IgG against VP1/VP2 proteins of parvovirus B19 in children and young adults (2–18 years)

Figure 7

Table 4(a). Prevalence of IgG against VP1/VP2 proteins of parvovirus B19 in different age groups of adult men and women working in occupational fields with frequent contacts with either children or patients

Figure 8

Table 4(b). Prevalence of IgG against VP1/VP2 proteins of parvovirus B19 in different age groups of adult men and women living in households together with one or more children aged <6 years or between 6 and 18 years